Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 Clinical Trials
20 clinical trials for Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.
- Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial — RECRUITING · PHASE2
- mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma — RECRUITING · PHASE3
- Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors — RECRUITING · PHASE1
- Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors — RECRUITING · PHASE1
- Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors — RECRUITING · PHASE2
- Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma — RECRUITING · PHASE2
- Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer — RECRUITING · PHASE2
- CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors — RECRUITING · PHASE2
- Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer — COMPLETED · PHASE1
- Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers — ACTIVE_NOT_RECRUITING · PHASE1
- Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer — ACTIVE_NOT_RECRUITING · PHASE2
- Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma — ACTIVE_NOT_RECRUITING · PHASE1
- Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines — ACTIVE_NOT_RECRUITING · PHASE1
- Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial — ACTIVE_NOT_RECRUITING · PHASE1
- Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma — NOT_YET_RECRUITING · PHASE1
- National Cancer Institute "Cancer Moonshot Biobank" — ACTIVE_NOT_RECRUITING
- Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer — ACTIVE_NOT_RECRUITING · PHASE1
- Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
- Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study — COMPLETED
- IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer — COMPLETED · PHASE1
Refine this search